{"groups":[{"description":"neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m\\^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.","id":"FG000","title":"Neratinib Plus Capecitabine"},{"description":"lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m\\^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.","id":"FG001","title":"Lapatinib Plus Capecitabine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"212"},{"groupId":"FG001","numSubjects":"240"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"10"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"64"}],"type":"Discontinuation of study by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Randomized in Error"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"307"},{"groupId":"FG001","numSubjects":"314"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"303"},{"groupId":"FG001","numSubjects":"311"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"307"},{"groupId":"FG001","numSubjects":"314"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}